Onco Wiki / Maladie

Carcinome nasopharyngé (NPC)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-NPC
TypeMaladie
Alias
Carcinome nasopharyngé associé au VEBNPCCarcinome nasopharyngéCancer du nasopharynxCarcinome nasopharyngé indifférenciéНазофарингеальна карцинома
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-IARC-MONO-100B-2012 SRC-NCCN-HNSCC-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8071/3
icd_o_3_topography["C11"]
icd_10C11
who_classificationWHO Head and Neck Tumours 5th ed (2022): Non-keratinizing nasopharyngeal carcinoma (EBV-associated) + keratinizing variants

Capacités

Notes

Distinct from other head/neck SCCs: EBV-associated, lymphoepithelial histology, very chemo- and radio-sensitive, distinct anatomic challenges (skull-base proximity, retropharyngeal nodal drainage). Treatment: definitive concurrent chemoradiation for locally advanced disease (cisplatin + IMRT); induction chemo (gemcitabine + cisplatin) showing OS benefit in recent trials. Metastatic 1L: gemcitabine + cisplatin + toripalimab or camrelizumab (PD-1) per recent Chinese Phase 3s. Plasma EBV-DNA used for post-treatment surveillance — rising levels predict relapse months before imaging.

Utilisé par

Algorithmes

Indication

Signal d’alerte

Sources